Huntington National Bank Sells 144 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Huntington National Bank trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,986 shares of the medical equipment provider’s stock after selling 144 shares during the period. Huntington National Bank’s holdings in Zimmer Biomet were worth $646,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. M&G Plc bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $7,397,000. Gradient Investments LLC boosted its stake in shares of Zimmer Biomet by 17.3% in the second quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock valued at $14,147,000 after purchasing an additional 19,224 shares during the period. National Pension Service grew its position in shares of Zimmer Biomet by 3.8% during the third quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after buying an additional 13,612 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Zimmer Biomet by 7.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock worth $30,265,000 after acquiring an additional 15,548 shares in the last quarter. Finally, Swedbank AB acquired a new stake in shares of Zimmer Biomet during the first quarter worth about $2,740,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Up 3.4 %

Shares of ZBH stock opened at $112.54 on Friday. The stock has a 50 day simple moving average of $106.28 and a 200 day simple moving average of $110.11. The stock has a market cap of $22.40 billion, a P/E ratio of 21.40, a price-to-earnings-growth ratio of 2.00 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $1.65 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. Zimmer Biomet’s payout ratio is 18.25%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZBH shares. BTIG Research reduced their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Wells Fargo & Company increased their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Wolfe Research began coverage on Zimmer Biomet in a report on Tuesday, September 10th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. lowered their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, September 16th. Finally, TD Cowen cut their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.